Expression of Heat Shock Protein 90 in Testicular Cancer: A Retrospective Cohort Study.

IF 1.4 Q4 PHARMACOLOGY & PHARMACY
Konstantinos Tzelepis, Ilias Giannakodimos, Vasileios Politis, Konstantinos Stamatiou, Ioannis Provatas, Evangelia Mitakidi, Vasileios Tzortzis, Sotirios Sotiriou
{"title":"Expression of Heat Shock Protein 90 in Testicular Cancer: A Retrospective Cohort Study.","authors":"Konstantinos Tzelepis, Ilias Giannakodimos, Vasileios Politis, Konstantinos Stamatiou, Ioannis Provatas, Evangelia Mitakidi, Vasileios Tzortzis, Sotirios Sotiriou","doi":"10.2174/0115748871317252240919051309","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The HSP90 marker is believed to play a constructive role in facilitating neoplastic transformation mainly via interaction with multiple pro-survival proteins. Welldesigned studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.</p><p><strong>Objective: </strong>The current study aimed to investigate the expression of HSP90 in various types of testicular cancer and highlight its expression in embryonal testicular cancer.</p><p><strong>Material and methods: </strong>Immunohistochemical staining for HSP90 in 84 male patients, with nonmetastatic testicular cancer, who underwent orchiectomy from 2000 to 2023, was retrospectively performed at the Laboratory Department of General Hospital of Nikaia in Greece.</p><p><strong>Results: </strong>A total of 84 males, with a mean age of 36.2 years, who have undergone high-cord radical orchiectomy, were included in this study. Out of the included males, 28.57% had embryonal carcinoma, 23.81% had seminoma, 19.05% had yolk sac tumor, 11.9% had mature teratoma, 9.52% had immature teratoma, and 7.14% had choriocarcinoma. HSP90b was positive in all embryonal carcinoma, seminoma, and choriocarcinoma cases, while it was positive in 75% of the yolk sac tumor, 75% of mature teratoma, and 75% of immature teratoma specimens. HSP90 was found negative in all choriocarcinoma, mature teratoma, and immature teratoma specimens, while it was positive in 25% of yolk sac tumor, 8.33% of embryonal carcinoma, and 10% of seminoma cases. Concerning the expression of HSP90b, a statistically significant relationship was found between excised tumor specimens and normal parenchyma specimens, especially in sac cases (p <0.001). Regarding HSP90a expression, a statistically significant relationship (OR=21.5, p =0.021) was found between excised tumor specimens and normal parenchyma specimens, especially in embryonal carcinoma cases (p <0.001).</p><p><strong>Conclusion: </strong>HSP90b is highly expressed in the majority of the types of testicular tumors, both in tumor and normal parenchyma specimens, while HSP90a staining is negative in resected specimens. Further well-designed studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871317252240919051309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The HSP90 marker is believed to play a constructive role in facilitating neoplastic transformation mainly via interaction with multiple pro-survival proteins. Welldesigned studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.

Objective: The current study aimed to investigate the expression of HSP90 in various types of testicular cancer and highlight its expression in embryonal testicular cancer.

Material and methods: Immunohistochemical staining for HSP90 in 84 male patients, with nonmetastatic testicular cancer, who underwent orchiectomy from 2000 to 2023, was retrospectively performed at the Laboratory Department of General Hospital of Nikaia in Greece.

Results: A total of 84 males, with a mean age of 36.2 years, who have undergone high-cord radical orchiectomy, were included in this study. Out of the included males, 28.57% had embryonal carcinoma, 23.81% had seminoma, 19.05% had yolk sac tumor, 11.9% had mature teratoma, 9.52% had immature teratoma, and 7.14% had choriocarcinoma. HSP90b was positive in all embryonal carcinoma, seminoma, and choriocarcinoma cases, while it was positive in 75% of the yolk sac tumor, 75% of mature teratoma, and 75% of immature teratoma specimens. HSP90 was found negative in all choriocarcinoma, mature teratoma, and immature teratoma specimens, while it was positive in 25% of yolk sac tumor, 8.33% of embryonal carcinoma, and 10% of seminoma cases. Concerning the expression of HSP90b, a statistically significant relationship was found between excised tumor specimens and normal parenchyma specimens, especially in sac cases (p <0.001). Regarding HSP90a expression, a statistically significant relationship (OR=21.5, p =0.021) was found between excised tumor specimens and normal parenchyma specimens, especially in embryonal carcinoma cases (p <0.001).

Conclusion: HSP90b is highly expressed in the majority of the types of testicular tumors, both in tumor and normal parenchyma specimens, while HSP90a staining is negative in resected specimens. Further well-designed studies are needed to elucidate the role of HSP90 as a diagnostic marker and therapeutic target in testicular tumors.

睾丸癌中热休克蛋白 90 的表达:一项回顾性队列研究
背景:据信,HSP90标记物主要通过与多种促生存蛋白相互作用,在促进肿瘤转化方面发挥建设性作用。要阐明 HSP90 在睾丸肿瘤中作为诊断标记物和治疗靶点的作用,需要进行精心设计的研究:本研究旨在调查 HSP90 在各种类型睾丸癌中的表达,并强调其在胚胎性睾丸癌中的表达:希腊尼卡亚综合医院检验科对2000年至2023年期间接受睾丸切除术的84名非转移性睾丸癌男性患者进行了HSP90免疫组化染色:本研究共纳入 84 名接受过高脐根治性睾丸切除术的男性,他们的平均年龄为 36.2 岁。在这些男性患者中,28.57%患有胚胎癌,23.81%患有精索瘤,19.05%患有卵黄囊肿瘤,11.9%患有成熟畸胎瘤,9.52%患有未成熟畸胎瘤,7.14%患有绒毛膜癌。HSP90b在所有胚胎癌、精原细胞瘤和绒毛膜癌病例中均呈阳性,而在75%的卵黄囊肿瘤、75%的成熟畸胎瘤和75%的未成熟畸胎瘤标本中均呈阳性。HSP90在所有绒毛膜癌、成熟畸胎瘤和未成熟畸胎瘤标本中均为阴性,而在25%的卵黄囊肿瘤、8.33%的胚胎癌和10%的精原细胞瘤中呈阳性。关于 HSP90b 的表达,切除的肿瘤标本与正常实质标本之间存在统计学意义上的显著关系,尤其是在卵黄囊病例中(p 结论:HSP90b 在卵黄囊肿瘤中高表达:在大多数类型的睾丸肿瘤中,HSP90b在肿瘤和正常实质标本中均高表达,而在切除标本中HSP90a染色为阴性。要阐明 HSP90 在睾丸肿瘤中作为诊断标记物和治疗靶点的作用,还需要进一步开展精心设计的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reviews on recent clinical trials
Reviews on recent clinical trials PHARMACOLOGY & PHARMACY-
CiteScore
3.10
自引率
5.30%
发文量
44
期刊介绍: Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信